This comprehensive meta-analysis of 11 randomized controlled trials, encompassing over 23,000 patients across the full spectrum of heart failure phenotypes, provides robust and consistent evidence that SGLT2 inhibitors confer clinically meaningful and patient-centered benefits regardless of ejection fraction, diabetes status, or clinical setting. Here, SLC5A2 is linked to heart failure.